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Metastatic cancer is rarely cured by current DNA damaging treatments, apparently due to the development of
resistance. However, recent data indicates that tumour cells can elicit the opposing processes of senescence and
stemness in response to these treatments, the biological significance and molecular regulation of which is currently
poorly understood. Although cellular senescence is typically considered a terminal cell fate, it was recently shown
to be reversible in a small population of polyploid cancer cells induced after DNA damage. Overcoming genotoxic
insults is associated with reversible polyploidy, which itself is associated with the induction of a stemness
phenotype, thereby providing a framework linking these separate phenomena. In keeping with this suggestion,
senescence and autophagy are clearly intimately involved in the emergence of self-renewal potential in the
surviving cells that result from de-polyploidisation. Moreover, subsequent analysis indicates that senescence may
paradoxically be actually required to rejuvenate cancer cells after genotoxic treatments. We propose that genotoxic
resistance is thereby afforded through a programmed life-cycle-like process which intimately unites senescence,
polyploidy and stemness.
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Accelerated cellular senescence (often simply termed
‘senescence’) has been enigmatic since its first description.
It was initially defined as an irreversible growth arrest
induced in proliferating cells by a variety of stress stimuli,
the most important being telomere attrition, DNA damage
[1] and oncogene activation [2]; the latter two paradoxically
representing cancer inhibiting and promoting responses,
respectively. The biology of senescence and cancer are
clearly closely related, although their inter-relationship
remains poorly understood [3,4]. Currently, the com-
plex regulation of these processes is thought to occur at
the interface of signalling pathways involved in growth-
arrest (p16INK4a/Rb and p19ARF/p53) and promotion
(mTOR) [2,5,6].
Phenotypically, the features of accelerated senescence
overlap with those of replicative senescence caused by
telomere shortening; namely enlarged and flattened cell
shape, increased cytoplasmic granularity, polyploidy, and* Correspondence: katrina@biomed.lu.lv
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distribution, and reproduction in any mediumexpression of senescence-associated β-galactosidase
(SA-β-gal) [7,8]. Hypertrophic senescent cells are also
immunomodulatory and secrete cytokines [4]. Perhaps
paradoxically, senescent cells can be cleared by CD4+ T
cells and macrophages; however, if the immune response
is suppressed, cancer develops [9,10]. The question then
arises: Why do senescent cells which do not proliferate,
pose a cancer risk and require elimination? This raises the
possibility that at least a proportion of these cells can revert
from terminal senescence [11]. In this article we review the
recent evidence supporting this possibility and provide
a hypothesis for the molecular and biological basis for
how reversion may occur through induced polyploidy
and reprogramming for totipotency.Escape from genotoxic insults is associated with
reversible polyploidy
DNA and spindle damage induce polyploidy in tumour cells,
particularly when TP53 function is absent or dysregulated.
Although previously the induction of polyploidy was viewed
as a reproductive dead end, evidence has now accumulated
(reviewed in [12-14]) to indicate that this is not the case.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Erenpreisa and Cragg Cancer Cell International 2013, 13:92 Page 2 of 12
http://www.cancerci.com/content/13/1/92Using various DNA or spindle insults the reversibility
of induced polyploidy was shown definitively by direct
time-lapse imaging [15-18] and/or isolation of the
polyploid fraction with subsequent sub-cloning. These
cells can return to mitotic para-diploidy, giving rise to
damage escape clones providing clonogenicity in vitro
[19-21], and rapid malignant growth in vivo [20,21]. The
reversible polyploidy observed in these DNA-damaged
tumour cells is however a complex, protracted process
successfully giving clonogenic escape to only 10-4-10-6 of
the cells [8,20]. First, polyploidisation occurs in 10-50
% of the cells, reaching a peak on day 5 post-damage,
with ploidy numbers up to 32n. Extensive cell death
(by apoptosis or mitotic catastrophe) ensues leaving
only 10-20% of polyploid giant cells alive [19-21], some
of which undergo successful de-polyploidisation leading
to the establishment of the mitotically cycling survivors
from days 7–14 post-damage, while the other survivors
slowly senesce [17-20]. Subsequent re-treatment of the
cells that recover elicits the same process again [19].
This approximate schedule detailed by us for irradiated
Namalwa and HeLa cells [22] is also observed in tumour
cell lines of multiple types and species treated with different
genotoxic stimuli suggestive of a common underlying
biological process with absence of TP53 function [19,21]
or equivalent loss of the cell cycle control [20,23] a pre-
requisite for its success.
Somatic polyploidy (endopolyploidy) can be reversible
and irreversible, differing in several key aspects. Irreversible
polyploidy [24-26] occurs through re-replication in the ab-
sence of mitosis and can reach very high levels of genome
duplication (up to several thousand or more), for example
in the salivary glands of Diptera [27] and in the giant cells
of the rodent trophoblast [28]. In contrast, endopoly-
ploidy of mammalian hepatocytes and cardiomyocytes
occurs through aborted mitoses, is less extensive; and
typically does not revert [25,26], although it retains this
potential [29,30], while transient polyploid mammalian
tumour cells, which typically also do not exceed 32n,
can revert to mitosis and initial para-diploidy [31-33].
In tumours, this process is induced by DNA or spindle
damage and occurs by aborted mitosis - ‘mitotic slippage’
(reset of tetraploid interphase from aborted metaphase)
or by a-cytotomic DNA-bridged bi-polar mitosis starting
endopolyploidy from bi-nuclearity and often followed by
multi-nucleation [22,23,25,32,34].
Another peculiar feature of the transient polyploidy is
that the tumour cells thus by-pass mitotic catastrophe
(thereby uncoupling the spindle checkpoint from apoptosis)
[35] and enter tetraploidy with unrepaired DNA double
strand breaks (DSB). During the ensuing polyploidisation
cycles these breaks are repaired by homologous recom-
bination, which is also uncoupled from apoptosis [32].
This behaviour supports the idea that entering polyploidyis part of a tightly programmed process that provides a
powerful survival advantage to cells carrying DNA damage
and that the whole process has a clear purpose.
It should be noted that cell fusions may also give rise
to polyploidy [36] or perhaps the parasexual events
represent an intermediate step in the process of revers-
ing tumour cell polyploidy, however their importance
and sequence in this process is unclear. Similarly, although
the means and consequences of the divisions that the
polyploidy tumour cells undergo have been extensively
studied and discussed [25,34,37,38], currently the con-
tribution and significance of each (for example bi-polar
symmetric and asymmetric, reductional, multi-polar
(single and repeated) divisions and segregation of whole
genomes [21-23,31,39-41]) for clonogenic survival after
DNA damage is unclear. However, two of these may well
be of central importance: (1) cell divisions with meiotic
features – i.e. those featuring cohesed sister chromatids
(segregating diplochromosomes or synapsed homologs),
such as observed in 4n-8n cells [40-44] and (2) de-
polyploidisation of the high ploidy cells (16n-32n) which
is completed by budding of para-diploid daughters, and
perhaps represents the final stage in the step-wise survival
process [17,31,39,42,45-47] (see below).
Our studies revealed that cyclin B1 and Aurora B kinase
overexpressed in endopolyploid tumour cells are important
regulators of the transition from the normal mitotic cycle
to tetraploidy [22,32]. In line with this conclusion, Marxer
et al. reported that tetraploid cancer cells are particularly
sensitive to inhibition of Aurora B-kinase [48] and that
the underlying mechanism is due to mitotic slippage
and subsequent endoreduplication.
Reversible polyploidy coincides with reversible senescence
Accelerated senescence is also a product of DNA damage
in treated tumour cells [1] and recent evidence has in-
dicated that it may be reversible [49-52]. Puig et al. [20]
have previously suggested that reversible polyploidy of
genotoxic-damage induced tumour cells is associated
with reversible senescence of the sa-β-gal-positive cells,
a proposal supported by Daniel Wu’s group. The latter
showed that escape from accelerated senescence in both
a p53-null non small cell lung cancer cell-line (NSCLC)
in vitro and in primary tumours is due to overexpression of
cdk1 [53] and survivin [54] and that aberrant expression of
cdk1 promotes the formation of polyploid senescent cells,
which are an important intermediary through which escape
preferentially occurs [55]. Cdk1 is a catalytic unit of cyclin
B1 regulating entrance into mitosis, while Aurora B-kinase
alongside INCENP and survivin regulate correct attach-
ment of spindle microtubules to kinetochores [22,56]. As
such, it appears that the illicit transition of cells from the
mitotic cycle into polyploidy, induced by DNA damage,
paradoxically needs mitosis regulators and can be reversed.
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the same damage and depends on a common pathway
in a diverse array of tumour cells (human lymphoma,
cervical and lung cancer, rat colon cancer, and mouse
osteosarcoma). Moreover, this transition programme
has an additional dimension, most notably its ability to
re-activate signalling pathways associated with meiosis
and pluripotency.
Activation of meiotic genes during reversible polyploidy
Our first observations of reversible polyploidy in irradiated
TP53 mutant Burkitt’s lymphoma cells induced by
DNA damage lead us to propose an analogy with the
evolutionarily-conserved ploidy cycles of unicellular
organisms [31]. It was based upon the view that the
ploidy cycles (reversible polyploidy) of unicellularians
evolved from mitosis to cope with DNA damage and
served as the evolutionary precursors of meiosis and
sexual life-cycles [57,58]. This hypothesis is supported by
the close analogy observed between the signalling pathways
responding to exogenous and endogenous DSB introduced
by DNA damage and the meiotic nuclease SPO11, respect-
ively, evident in the molecular identity between the mitotic
G2M DNA damage checkpoint and the recombination
checkpoint of meiotic prophase [59]. As clear confirmation
of their homology, sterile SPO11 mutants of C. elegans
can be rendered fertile by the application of radiation
eliciting DNA DSB [60]. The idea that cancer cells may
be exploiting processes similar to these ancient unicellurian
ploidy cycles to recover from DNA damage and to support
their immortality was gradually developed in a series of arti-
cles [31,43,61-63] resulting in the concept of a ‘cancer cell
life cycle’ assigning germline properties to the recovering
cells. In line with this suggestion, up-regulation of key
meiotic genes (MOS, REC8, SGO1, SGO2, DMC1, SPO11,
SCYP1,2,3, STAG3) was found and associated with revers-
ible polyploidy in TP53-deficient lymphoma, breast, colon,
ovarian, and cervical cancer cell lines after irradiation
or spindle damage [21,23,43,61,64]. In addition, ectopic
expression of some key meiotic genes was also reported
in primary tumours, for example MOS in NSCLC [65],
DMC1 in cervical cancer [23], SPO11, REC8, SGO1 and
HORMAD1 in melanoma [66]. In particular, activation
of Mos kinase in tumour cells after DNA damage was
reported as being coincident with overcoming prolonged
G2-arrest [61,64] and necessary for the recovery of para-
diploid descendants from tetraploid cells formed after spin-
dle damage [21,61,63,64]. Key features of meiotic divisions
with the meiotic cohesin REC8 linking sister centromeres,
the meiotic recombinase DMC1 colocalising with DSB/
γH2AX foci, and the omission of S-phase before mitosis
were found in some polyploid lymphoma and HeLa cells
induced after irradiation [23,43]. Together this information
allows us to suggest that prolonged arrest of damagedtumour cells in G2 and their transition from it through
aborted mitoses into polyploidy (with its enhanced capacity
for DNA repair) as well as its reversal may be associated
with the induced meiosis-like programme. In particular, the
aberrant accumulation of Mos-juxta-localised cyclin B1
in endomitotic cells, as well as the upregulation of Aurora
B-kinase, both involved in many meiotic processes [59]
may be critical for this transition towards polyploidy and in
preparing for its reversal. Intriguingly, the same complexes
(cdk1/ cyclin B1 and Aurora B-kinase/survivin) are also
involved in reversing senescence [53-55].
Accelerated senescence has overlapping molecular
pathways with gametogenesis
Further links between senescence and meiosis can be
found in the signalling pathways of two prominent proto-
oncogenes, mos and ras. As reported above, mos activation
is induced by DNA- or microtubule-damaging agents
in TP53-mutated somatic tumour cells of various ori-
gins in association with their illicit shift to tetraploidy
[21,23,61,63,64]. Mos, also known as MAP kinase kinase
kinase, is a key driver of meiosis in the animal kingdom
[59,67,68]. In female meiosis, activated Mos causes oocyte
maturation – inducing the first meiotic division of the
oocytes paused at G2 phase-like prophase (by activating
cdk1/cyclin B1), triggering interkinesis with suppression
of DNA synthesis, and causing the subsequent arrest at the
spindle checkpoint of meiosis II. Here, Mos prevents par-
thenogenesis in the mature oocytes awaiting fertilisation,
through the MEK-pMAPK42-Rsk90 complex and also by
acting directly on the meiotic spindle [59,63,67-69]. Mos is
downstream of Ras in meiosis and equivalent to Raf in the
Ras-MEK-MAPK proliferative pathway. All constitutively
active downstream effectors of Mos: MEK, MAPK, and
p90Rsk, are also able to induce meiotic maturation when
microinjected into oocytes [68]. Given its unique and
powerful role in meiosis, it is perhaps not surprising
that overexpression of Mos in somatic cells can cause
an oocyte phenotype [70,71]. However, Mos, like Ras, is
also oncogenic [68,71]. Conversely, the same members of
the Ras pathway, including Mos, can cause premature sen-
escence through a MEK-MAPK-dependent p16inka4-pRb
arrest of proliferation [7] and activate DNA damage sig-
nalling [72]. In fact, strong oncogenic signalling through
the constitutively active H-rasVal12 mutant is routinely used
experimentally as a means to rapidly induce senescence [2].
Intriguingly however Ras is required for meiosis as part of
the productive germline programme (reviewed in [70,71])
during the switch from meiosis to mitosis when it acti-
vates the cleavage divisions after fertilisation of the ma-
ture egg [68,71,73]. The activation of the mature oocyte
to initiate post-fertilisation or parthenogenetic cleavage
cycles also involves the activity of Akt and PKCα, which
can be stimulated by activated Ras and likely mTOR
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in cancer [75,76].
Ras can also, directly and equivalently substitute for
endogenous Mos in frog oocyte maturation [77]. More-
over, mutant H-rasVal12 is nearly 100-times more potent at
inducing maturation [77]. It, unlike Mos, does not need
stimulation by progesterone and can promote entry into
meiotic M phase and cdk1 activation independently of
Mos [69]. Clearly then the molecular pathways induced by
DNA damage and involved in the illicit transition to
tetraploidy and accelerated senescence (which should
terminate proliferation), are intrinsically associated with
the molecular pathways of gametogenesis and early
embryogenesis (which, in contrast, can restore immortality
and re-initiate the life-cycle) potentially allowing this switch
between them.
Reversible polyploidy is associated with induction of the
ESC-type stemness
Since their description, cancer stem cells have been as-
sociated with resistance to genotoxic therapy [78,79].
In addition, a stem-like gene signature has been associated
with aggressive tumours of various origins in vivo [80-82],
while down-regulation is reported to cause suppression of
tumour growth and invasion [83]. Typically resistance to
therapy is attributed to the intrinsic properties of stem cells,
most notably their enhanced expression of ABC drug efflux
pumps, augmented DNA repair capacity and resistance
to apoptosis [84], however an alternative possibility of
stemness induction in differentiating tumour cells has
also been proposed [85]. Our own observations on the
induction and reversal of polyploidy favour the latter
hypothesis. We established that the key pluripotency
and self-renewal cassette (OCT4, NANOG and SOX2)
was also induced after DNA and spindle damage in several
tumour cell types [45,86].
Importantly, the core stemness gene expression cassette
(OCT4, NANOG, SOX2) was observed to be induced in
the vast majority of G2 - 4C cells before any completed cell
division, precluding the possibility that rare DNA-damage
resistant stem cells had been selected. The induction of
stemness by DNA damage was further confirmed after
separating phenotypically distinct tumour cell populations
possessing or lacking stem cell markers from myeloid
[87], hepatocellular [88] and breast tumour cell lines [89].
These studies showed that irradiation of differentiated
(non-stem cell phenotype) tumour cells caused phenotypic
shift to a stem cell-like state (as confirmed by the appropri-
ate markers), with the associated transcriptional profiles,
enhanced clonogenicity, growth as 3D-spheres and xeno-
transplantation activity. Moreover, Lagadec and colleagues
[89] convincingly showed that shift of breast cancer cells
(including primary clinical material) to the pluripotency
state by ionising irradiation occurs principally in theinduced polyploid subpopulation. The link between in-
duced tumour cell endopolyploidy and stemness reported
by these authors on breast cancer is in accordance with our
data on lymphoma and HeLa cells [86] and so supports the
existence of a general mechanism.
We showed that this induction is associated with the
transition from the mitotic cycle to tetraploidy and is
pre-empted by the appearance of nuclear OCT4 foci at
promyelocytic (PML) nuclear bodies which further re-
cruit the other members of the core ESC cassette, while
treatment with retinoic acid which suppresses the OCT4
promoter leads to dissociation of OCT4 from PML bod-
ies, loss of nuclear localisation and the absence of Nanog
[86]. In accordance with this observation, PML protein
was reported to be required for activating chromatin
remodelling of the Oct4 promoter in stem cells [90],
while Bartova and colleagues showed in ESC that OCT4
becomes recruited to chromatin at sites of DNA damage
[91]. Oct-4 was further shown to be critical for the sur-
vival/apoptosis-resistance of murine ES cells subjected
to stress through interactions with Stat3 and survivin
[92]. The question arises then how these pluripotency
factors, induced by DNA damage interact with the sen-
escence machinery.
Senescence meets with stemness at the DNA damage
checkpoint
In experiments with normal IMR90 fibroblasts where
pluripotency was induced by retroviral transfection of
the Yamanaka factors (oct4, sox2, klf4 and c-myc) [93], a
concomitant and prevailing emergence of senescence
was seen [4,94], due to the upregulation of the cell cycle
inhibitors p16Ink4a, p15Ink4b and Arf [95]. These observations
are interesting because induction of stemness in tumour
cells by DNA damage might have mechanisms in common
with how normal cells may be artificially re-programmed to
become induced pluripotent stem cells (iPSC).
Subsequent research has shown that chromatin relax-
ation (by histone deacetylase inhibitors), suppression of
ROS, inhibition of mTOR, activation of glycolysis and
upregulation of autophagy, all improve iPSC reprogram-
ming efficiency. All of these mechanisms which serve to
decrease senescence and increase longevity illustrate
that accelerated senescence is an antagonist to, and natural
barrier for, reprogramming [6,96]. However, this model
does not explain why senescent cells, when allowed to
remain in the absence of a fully-functional immune system,
result in cancer progression [9-11].
We observed that when IMR90 fibroblasts are grown
in normal atmospheric oxygen they undergo limited
but appreciable polyploidisation at the pre-senescence
stage (very low mitotic index) through accumulation at
the G2/M DNA damage checkpoint [97]. A small pro-
portion of these cells (4-6%) overcome the barrier to
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damage (γH2AX positivity) [72,98], express the senescence
markers p16inka4a (CDNK2a) and p21 (CDKN1a), as well
as the self-renewal and pluripotency factor NANOG. Thus,
a mixed phenotype of accelerated senescence alongside
stemness markers appears at the abrogation of the DNA
damage checkpoint during the shift to tetraploidy. In fact,
this response is also characteristic for stem cells themselves
which lack the conventional G1/S checkpoint but retain
the checkpoint at G2/M [99] and can access reversible
polyploidy through mitotic slippage uncoupled from apop-
tosis during stress [100].
Moreover, Mantel et al. [100,101] showed that mitotic
slippage in stressed ESC is associated with a peculiar
sub-phase, where nuclear cyclin B1 remains undegraded.
This same unusual enrichment of cyclin B1 was found in
polyploid tumour cells induced by irradiation [32,61],
in parallel with the Aurora B-kinase enrichment [22].
Furthermore, overexpression of the catalytic subunit of
cyclin B1-was also found responsible for the polyploidy-
associated reversal of senescence in lung cancer [55]. It is
tempting therefore to link the ectopic expression of Mos
(which prevents the degradation of cyclin B1 in meiosis)
with the by-pass of mitotic catastrophe and slippage
into tetraploidy and endomitosis [61,63] as part of the
reprogramming process overcoming senescence. Next,
we must consider by which means induced polyploidy
can favour stemness.
Polyploidy, stemness and cancer share a glycolytic
metabolism
One of the keys to this puzzle was provided by the recent
work of Zhang et al. [47]. Using CoCl2 to induce hypoxia,
Zhang et al. showed that polyploid but not diploid ovarian
cancer cells are resistant to hypoxia and accumulate
the hypoxia-inducible factor HIF-1α, a key regulator of
glycolysis. Individual polyploid tumour cells selected in this
way are positive in sphere formation and tumorigenicity
assays, and release small clonogenic descendents by
asymmetric division and budding. Growth in the presence
of hypoxia indicates a reliance of the polyploid giant cells
on a more glycolytic energy generation pathway uniting
polyploidy with the stemness phenotype as discussed by the
authors [47]. An increased glycolytic flux as an outcome of
whole-genome duplication was found in yeast [102] and
also reported in endopolyploid mouse hepatocytes and
human cardiomyocytes [103]. The preferential use of the
aerobic glycolytic energy source by tumour cells discovered
by Otto Warburg nearly a century ago is now recognized as
a key means of metabolic reprogramming [104], while in-
creased glycolysis coupled to increased nucleotide and lipid
synthesis is a hallmark uniting tumours of various origins
[105]. Zhang et al. also reported that these CoCl2-selected
polyploid cells of ovarian cancer lacked sa-gal-β-positivityand that their budded descendents acquired a mesenchymal
phenotype [47]. The epithelial mesenchymal transition
(EMT), which is a key phenotypic link in cancer pro-
gression, is known to be associated with glycolysis/
HIF-1α -dependent metabolic shift, conferring a powerful
growth advantage for tumours in hypoxic conditions. EMT
is itself associated with increased stemness – i.e. phenotypic
plasticity, sharing properties with cancer stem cells and
metastatic cancer [106]. Thus EMT coupled to the shift in
metabolism may be interpreted as a key step away from
senescence. Interestingly, c-Myc is known to activate glu-
tamine consumption and many of the genes involved in
glucose metabolism contributing directly to the Warburg
effect [107]. It is furthermore linked with mTOR – a central
activator of the Warburg effect in the HIF-1α-mediated
glycolysis signaling network [108].
Moreover, c-Myc is long known as a powerful frequently-
activated oncogene conferring immortality to cancer cells
[71] and perhaps most critically, it is a key reprogramming
gene, targeting a large subset of the ESC- module genes,
including telomerase [109]. As detailed above, it is also one
of the four Yamanaka transcription factors originally de-
scribed for the generation of iPSC. In addition, c-Myc
directly activates DNA replication [110], with its over-
expression uncoupling DNA replication from mitosis,
thereby favouring polyploidy [111]. Furthermore, there
is evidence that c-Myc is involved in polyploidisation of
normal mouse hepatocytes; in particular it was shown
that c-Myc accelerates hepatic ploidy in transgenic mouse
models [112]. c-Myc also up-regulates Aurora B kinase
[113] which is implicated in the maintenance of the malig-
nant state and in mitotic slippage [48]; all effects which
could contribute to the induction and maintenance of re-
versible polyploidy. Therefore, the switch to a glycolytic
metabolism involving constitutional activation of c-Myc
can be suggested as a key molecular event linking revers-
ible polyploidy to stemness, immortality, and likely EMT
phenotype of depolyploidised descendants and as a means
of shifting from senescence towards cancer progression. It
also worth noting that c-Myc accumulates extensively in
the cytoplasm of maturing oocytes, before migrating rapidly
into the nucleus upon fertilization [114]. This phenomenon
may represent the key mechanism of germline immortalisa-
tion [71] that be shared with the programmed reversible
polyploidy of tumour cells.
Induced stemness and accelerated senescence emerge in
the same polyploid cells
Since the first observations by Roninson over a decade ago
[1], it has been known that DNA damaging drug treatments
cause cellular senescence with permanent growth arrest of
tumour cells. Moreover, as mentioned above, induced poly-
ploidy is regarded as part of this process. At the same time,
there are convincing data (initiated by the observations of
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century ago) suggesting that aneuploidy resulting from
the emergence of tetraploidy is intimately involved in
cancer initiation and progression [25,34,38,115]. However,
it now seems possible that the induction of stemness in
the induced tetraploid cells might be the primary driver
of this effect, with genome instability and aneuploidy a
secondary event.
The question then becomes how does the senescence
machinery interact with that regulating stemness in these
polyploid cells? Are they friends or enemies? Here we
should consider two different phases of the DNA damage
response: (1) the early response occurring at the G2 DNA
damage checkpoint and the adaptation into tetraploidy, and
(2) the later events in the smaller cohort of tumour cells
which display higher levels of polyploidy and finally de-
polyploidise by budding. In the former induced stemness
becomes coupled with senescence by adapting the tetra-
ploidy barrier [97,116] possibly through the activation of
meiotic genes as discussed above. In contrast, in the second
phase of the response, stemness is apparently progressed
and dissociates from senescence [17,45,47].
Phenotypic bi-potentiality of the tetraploid tumour cells
induced by DNA damage
As already mentioned above, the first stage of the DNA
damage response is characterised by bi-potentiality,
an observation that is supported from parallel studies
on oncogene-induced senescence. Sherman et al. [117]
showed that immortalised breast epithelial cells transduced
by an oncogene do not undergo terminal growth arrest, but
instead display a dual state defined as ‘senescence with
incomplete growth arrest’ or SWING, whereby ‘senescent’
cells stained for sa-β-gal simultaneously express the prolif-
eration marker Ki67 and occasionally divide [117]. It is
interesting to note that Ki-67-positivity was also described
as a feature of polyploidising human trophoblasts emerging
initially through restitution cycles (mitotic slippage) [118].
‘SWING’ is dependent on TP53, its downstream cell
cycle kinase inhibitor, p21cip1 (CDKN1a) and telomerase
competency [117]. Our most recent study of a TP53- and
telomerase-functional embryonal ovarian carcinoma PA1
[116] is somewhat in accord with the above. Following
etoposide treatment we showed a TP53-dependent induc-
tion of the self-renewal factor OCT4A alongside G2 arrest
and the induction of the senescence regulator p21cip1. As
before, expression of both these factors was observed in the
cells at the G2/M checkpoint and continued in tetraploid
cells. Highly heterogenous levels of OCT4A and p21cip1
were found in these cells, indicating a maintenance of insta-
ble bi-potentiality for the two opposing cell fates. Silencing
of TP53 lead to premature diversification of these fates,
resulting in highly aberrant multicentrosomal divisions and
senescence with up-regulated p16(inka4a) and sa-β-gal, andincreased DNA damage signaling (chk2). Interestingly,
competitive relationships between OCT4 and p21cip1 were
also revealed in ESC [119]. There, the p21cip1 promoter
was a direct repressional target of OCT4, leading the
authors to propose that this function of OCT4 may
contribute to the maintenance of ESC proliferation.
Another study [120] treating transformed fibroblasts
with etoposide revealed that silencing of p21cip1 para-
doxically lead to a decrease of Rad51 repair foci and in-
creased apoptosis, while Zheng and colleagues showed
that polyploid cells rewire the DNA damage response
and repair networks to escape senescence [121]. Col-
lectively these data suggest that the two opposing regu-
lators (Oct4 and p21cip1) initially cooperate to support
DNA damage repair, division potential, and protection
from aneuploidy. Our findings in embryonal carcinoma
underscore that the process following DNA damage occurs
in TP53-functional and telomerase competent tumour cells
through an intermediate state, which is bi-potential,
unstable and perhaps non-determined in respect of individ-
ual cell fates. Apparently, this dynamic type of regulation
including stochastic elements may be important for the
plasticity of the stem cell-like phenotype [122,123].
Release of rejuvenated descendants is associated with
rejection of senescence by autophagy
In the final stages of depolyploidisation, paradiploid progeny
derive from the polyploidy “mother” cell. According to the
‘neosis’ hypothesis proposed by Rajaraman and colleagues
[12,124] based on live-cell imaging and sub-cloning studies
[17], tumour cell immortality was gained through the acqui-
sition of transient stemness during this process. Accord-
ingly, transient stemness is induced during the generation
(“birth”) of rejuvenated de-polyploidised descendants from
the senescing polyploid “mother” cell through budding.
Weihua and colleagues manually isolated individual mouse
osteosarcoma polyploid cells from untreated cultures and
showed them to be sa-β-gal-positive, but also capable to
grow as spheroids, produce normal-sized cells resistant to
chemotherapy, and give rise to tumours and lung metastasis
in vivo [125]. Observations by Rajaraman’s group were
supported and extended by our findings [45] demonstrating
that the nuclear markers of stemness that initially ap-
pear in the majority of tetraploid cells induced by DNA
damage, only persist and accumulate in rare, highly
polyploid (16-32n) cells surviving into the second week
post-damage (while the other giant cells undergo mitotic
catastrophe, apoptosis or irreversible senescence). In these
surviving polyploid cells a-cytotomic multipolar radial div-
ision occurs followed by differentiation of subnuclei. Some
subnuclei continue to accumulate OCT4/NANOG/DMC1
germline markers, while others halt DNA synthesis, lose
these markers and undergo selective autophagic sequestra-
tion and degradation within the viable polyploid mother
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responsible for sa-gal-β-positivity [126], becomes involved
in sorting and dismantling the degenerated sub-nuclei and
facilitates the release of the rejuvenating subnuclei, which
then organise their individual cytoskeleton and cytoplasm
and bud away [31,39,45], much as described by others
[17,42,47]. These latter authors indicated that a stable EMT
phenotype is established in the budding tumour cells. Thus,
stemness, which appears first as an instable option in the
bi-potential tetraploid cells induced by DNA damage, can
pass through several endocycles, performing step-wise
recombination DNA repair, followed by segregation and
sorting of sub-nuclei, before it becomes stabilised and
independent from the polyploid “mother”. It should be
noted that during each polyploidisation cycle, cell fate
decisions are made, with the majority of cells deleted, as
can be seen from the progressively decreasing proportion
of cells that reach the limit of polyploidy (32n) [19,31,33].
The high DNA damage, step-wise character with negative
sorting, and stochastic acquisition of a stem cell-like state
[87] may explain why only a negligible proportion of poly-
ploid cells (10-4-10-6) are able to accomplish it.
Immunogenicity of polyploidy cells and its disappearance
Tumour cells are almost de facto immunogenic, based
upon their inherent mutations, and genomic and proteomic
dysregulation. However, overcoming immunogenicity
has been recognised as a key hallmark of progressive
malignancy [127] being countered by numerous immune-
evading tumour mechanisms (reviewed in [128]. To date,
the best characterised group of tumour associated antigens
are the so-called cancer testes associated (CTA) antigens
encoded by genes that are normally expressed only in germ,
placenta and embryonal cells, but which become ectopically
expressed in various tumours [129]. Furthermore, the ex-
pression of immunogenic CTA is associated with poor prog-
nosis [129,130]. Some authors have further associated poor
prognosis specifically with the mitotic-meiotic transition in-
volving proteins such as REC8, SPO11 and others [66,131].
For these reasons, the immunogenic CTA proteins have
been pursued as targets for therapeutic cancer vaccines. Al-
though clinically disappointing, these studies have heralded
in an era where the complexity of the immune system and
the multifarious tumour-driven modes of immune suppres-
sion and evasion have come to be realised.
However, the question remains: why does the immune
system not delete these cancer cells? indicating that they
may evade immune control or detection in some way.
As a recent illustration, patients which show clear immune
responses against major CTA antigens in gastric cancer
(perhaps indicative of high CTA levels in the tumour)
have a poorer survival [132].
As already mentioned, senescent cells can be cleared
by CD4+ T cells and macrophages. This process appearsimportant for tumour control as if the immune response is
suppressed, cancer develops [9,10]. Recent work shows that
tetraploid cells specifically (in a colon cancer cell-line at least)
upregulate the immunostimulatory molecule calreticulin
on their cell surface [133] and appear to undergo immune-
mediated control and destruction [134]. Therefore, tetraploid
cancer cells, which are potentially dangerous precursors of
invasive aneuploidy [19-21,34,55] can be detected and con-
trolled by the immune system in a similar way to how sen-
escent cells are controlled. How then do we explain the
process by which tumour cells cause relapse after treatment?
One possibility comes from findings associated with
EMT and autophagy. It is known that autophagy positively
regulates the stem-like phenotype of cancer cells [135].
Moreover, cells undergoing EMT were shown to be able
to upregulate autophagic mechanisms which serve to
impair target recognition and lysis of tumour cells by
cytotoxic T lymphocytes (CTL) [136]. Within the revers-
ible polyploidy process outlined above, autophagy is also
upregulated during the senescence/stem cell reprogram-
ming phase and during the generation of the final diploid
progeny [45,46]. Therefore, as EMT is also likely to occur
during this final de-polyploidisation of giant cells [47] it is
possible that autophagy serves a similar role here, redu-
cing the immunogenicity of the polyploid cells and their
progeny. Perhaps, the removal of the external cytoplasm
of the polyploid mother cell in parallel with the sequestra-
tion in autophagosomes of the diminuted sub-nuclei de-
scribed by us previously [31,45,46] serves to reduce the
immunoreactivity of the rejuvenated descendents that are
released. In this way the polyploid giant cells expressing
immunogenic CTA-associated epitopes may also diminish
their CTL-reactivity and potentially avoid immune destruc-
tion. Therefore descendants of polyploid cells transferring
immortality to the next tumour cell generation need
both the re-establishment of the germline programme
(to up-regulate telomerase and restore self-renewal) and
senescence (to allow restructuring and release of the reju-
venated descendents with the aid of autophagy). Rejection
of the germline by the senescent deteriorating polyploid
mother cell involves the removal of the neo-immunogenic
cell surface allowing escape from the immune system.
In fact, this process, replicates exactly that which occurs
during a life-cycle. However, the significance of the
chromatin diminution which is observed, often extruding
the whole sub-nuclei, remains obscure. One possibility
by way of analogy is with the emission of the polar bodies
during oocyte maturation and activation [137]. Another
analogy may be found in the evolutionary karyology of
heterokaryotic protozoans.
Chromatin diminution in the life-cycle of Tetrahymena
In the life-cycles of some ciliates, such as Tetrahymena,


























Figure 1 Inter-relationships between reversible polyploidy,
senescence and stemness. This diagram highlights the
inter-relationships and shared molecular pathways between the
three processes of polyploidy, senescence and stemness. DNA
damage potentiates this process leading to arrest at the G2M
damage checkpoint from which cells that by-pass mitotic
catastrophe go on to enter the polyploid cycle, eliciting transient
stemness to overcome senescence. TP53 serves as a strong
negative regulator of the process, favouring arrest at G1, apoptosis
induction and inhibiting entry into polyploidy.
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The MA is degraded by nucleolysis and autophagy and be-
comes extruded [138] during the conjugation and meiosis
of the MI, whilst the removal of the MA prevents this
process (cited from [139]). Interestingly, extensive synthesis
of the Rad51 recombinase in the MA is a necessary pre-
requisite for successive meiosis of the MI [140]. A simi-
lar collaboration may be required between persisting
and further diminuted sub-nuclei in the late stage poly-
ploid tumour cells, in which the diminuted chromatin is
also enriched with Rad51 and Rad52 proteins [45]. As
commented by Zhang et al. [47] the budding of the EMT
descendants from the polyploid mother is reminiscent
of the sporogenesis seen in Radiolaria, in which cycling
polyploidy is part of the life-cycle [139]. The analogies
with protozoan ploidy cycles give support to the view
that these cancer cell life cycles recapitulate some features
of the earlier evolutionary ploidy cycles, preserved in some
extant unicellular protozoans [141].
DNA damage can reprogramme tumour cells to totipotency
Since the pioneering studies of Mintz and Illmensee
[142] it has been known that the genome of cancer cells
can prime embryonal development. The molecular events
induced in TP53 deficient tumour cells in response to
DNA damage indicate a re-activation of a meiosis-like
programme, a fundamental mechanism which serves to
maintain germline identity and provide the link between
the life-cycles. In addition, the core transcription cassette
of ESC appears to be evoked. The question then arises
how these two pathways are linked through the DNA
damage response. Earlier studies revealed that Oct-4 ex-
pression in the germline is regulated independently from
epiblast expression by its distal enhancer [143]. Additional
studies [144] showed that the OCT4 transcriptional net-
work might be part of the molecular signature of cells
from maternal origin from which the inner cell mass and
the ESC-associated pluripotency arise. In this way, Oct4
provides the continuity of the totipotency (life) cycle in
normal development. On the other hand, observations
[86,91,116] indicate that Oct4 is the first of the core
ESC cassette genes to respond to DNA damage both in
TP53 wild-type stem cells and TP53 mutant somatic
tumour cells. Here the function of the different OCT4
isoforms should be also considered [86,145]. Evidently,
both the DNA damage responding and the totipotency
carrying functions of Oct4 are evolutionarily coupled
and involved in the mitotic to meiotic transition of
tumour cells. It can therefore be further suggested that
Oct4, in its role as both a DNA damage-responder and
totipotency regulator, serves as a link between the
early meiosis-initiating and later cleavage-like events
of de-polyploidisation and budding that give rise to
the rejuvenated descendants.The feasibility of such a process is also seen from the
behaviour of ESC themselves: under special cultivation
conditions, both female and male cells show gametogenetic
potential: i.e. they are capable of undergoing meiosis,
oocyte maturation and parthenogenetic development
up to the blastocyst stage [146].
The formation of the endoclone by rejuvenated sub-
nuclei which acquire individual cytoplasm and initiate
mitoses within a single giant cell [31,45] and the potential
of these individual cells to form a sphere and induce ma-
lignant growth in vivo [47,89,125] is entirely in keeping
with the embryonal nature of this process. We previously
suggested that to achieve this stage, the tumour cells need
to undergo about four endocycles thus reaching the
‘developmental totipotency checkpoint’ [33].
Conclusion
The failure of current cancer treatments to successfully
eradicate metastatic disease, likely results from a misunder-
standing of the natural history of cancer. Rather than seeing
malignancy as a consequence of Darwinian microevolution
driven by stochastic mutations, it can be considered as the
result of a programmed response illicitly accessed by a few
key mutations. Thus the focus of research is transferred
from the bewildering multiplicity of mutations to the
key transcriptional programme that is accessed and the
underlying epigenetics. This programme appears to
have been imprinted through evolution to cope with
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of the genome. The mechanisms which gave rise first
to reversible polyploidy and then meiosis and sexual
life cycles in unicellurians allowing the transition to
multicellularity are in some way recapitulated during
carcinogenesis. Unfortunately, it appears that the same
programme is stimulated in response to genotoxic treat-
ments, leading to disease relapse.
The concepts discussed in this review and the latest
available data give credence to the existence of an evolu-
tionary ontogenetic relationship between senescence,
carcinogenesis and gametogenesis and explain the paradox
of involving senescence in carcinogenesis and editing the
immunogenicity of tumour cells. This view brings us to a
new twist in the centuries-old embryological theory of can-
cer (reviewed by Erenpreiss [71]) with reversible polyploidy
as a new aspect. While trying to unveil the relationships be-
tween the overlapping pathways of polyploidy, senescence
and stemness (depicted in Figure 1), we have highlighted
both the synergism and heterogeneity of opposing regula-
tors, the pleiotropism of key oncogenes and the plasticity of
cell fate determination. To fully understand these complex
regulations a systems biology approach is required and
this has already led to an interesting variant of the em-
bryological theory of cancer where ESC-like state attrac-
tion is intrinsically linked to ontogenesis and phylogenesis
[147,148]. Recognition that cancer, despite a diverse range
of causes and driving mutations, is due to a similar epi-
genetic acquisition of ilicit transcriptional programmes
may favour a shift away from current treatment paradigms
to a more holistic whole network approach. This shift is
apparently already underway [149-152].
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
Both senior authors have made substantial intellectual contribution to this
study. Both authors read and approved the final manuscript.
Authors’ information
JE and MSC, lead cancer research laboratories in Riga and Southampton,
respectively and collaborated both experimentally and theoretically on
identifying and understanding the role of reversible polyploidy in cancer
resistance over the last 15 years.
Acknowledgements
The authors greatfully acknowledge the contributions made by the authors
of the experimental work performed in our laboratories since our first
publication on reversible polyploidy in 2000. The authors are grateful to
Kirsten Walen for discussions on senescence and depolyploidisation aspects,
Eugenia V and Tatyana G Zybina for discussions on developmental
polyploidy, Francois Martin for discussions on reversible polyploidy, Harry
Scherthan for discussions on meiosis, Zane Kalnina for discussions on the
immunogenicity of tumours, Sui Huang and Alessandro Giulliani for
discussions on aspects of systems biology, and Helmut Zacharius for providing
literature on the gender aspects of parthenogenesis. The contribution of Prof.
Jānis O Ērenpreiss (1929–1996) relating to the gametogenetic theory of cancer
is gratefully commemorated. The e-version of his book cited in this review
can be found:http://bmc.biomed.lu.lv/en/research/directions-and-labs/cancer-research/cancer-research/j-erenpreisa-lab/. The study was supported
by the Latvian Science Council grant Nr 341/2012.
Author details
1Latvian Biomedical Research & Study Centre, Riga LV-1047, Latvia. 2Antibody
and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, General
Hospital, University of Southampton, Southampton SO16 6YD, UK.
Received: 19 May 2013 Accepted: 24 July 2013
Published: 11 September 2013References
1. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res 2003,
63(11):2705–2715.
2. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras
provokes premature cell senescence associated with accumulation of
p53 and p16INK4a. Cell 1997, 88(5):593–602.
3. Finkel E: Telomeres: keys to senescence and cancer. Lancet 1998,
351(9110):1186.
4. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS: The essence of
senescence. Genes Dev 2010, 24(22):2463–2479.
5. Hasty P, Sharp ZD, Curiel TJ, Campisi J: mTORC1 and p53: clash of the
gods? Cell Cycle 2013, 12(1):20–25.
6. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G: The hallmarks
of aging. Cell 2013, 153(6):1194–1217.
7. Campisi J, d’Adda di Fagagna F: Cellular senescence: when bad things
happen to good cells. Nat Rev Mol Cell Biol 2007, 8(9):729–740.
8. Wu PC, Wang Q, Grobman L, Chu E, Wu DY: Accelerated cellular
senescence in solid tumor therapy. Exp Oncol 2012, 34(3):298–305.
9. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D,
Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al: Senescence
surveillance of pre-malignant hepatocytes limits liver cancer
development. Nature 2011, 479(7374):547–551.
10. Hoenicke L, Zender L: Immune surveillance of senescent cells–biological
significance in cancer- and non-cancer pathologies. Carcinogenesis 2012,
33(6):1123–1126.
11. Serrano M: Cancer: final act of senescence. Nature 2011, 479(7374):481–482.
12. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR: Stem cells,
senescence, neosis and self-renewal in cancer. Cancer Cell Int 2006, 6:25.
13. Wheatley D: Growing evidence of the repopulation of regressed tumours
by the division of giant cells. Cell Biol Int 2008, 32(9):1029–1030.
14. Lee HO, Davidson JM, Duronio RJ: Endoreplication: polyploidy with
purpose. Genes Dev 2009, 23(21):2461–2477.
15. Ianzini F, Mackey MA: Development of the large scale digital cell analysis
system. Radiat Prot Dosimetry 2002, 99(1–4):289–293.
16. Prieur-Carrillo G, Chu K, Lindqvist J, Dewey WC: Computerized video time-lapse
(CVTL) analysis of the fate of giant cells produced by X-irradiating EJ30
human bladder carcinoma cells. Radiat Res 2003, 159(6):705–712.
17. Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R: Neosis: a novel
type of cell division in cancer. Cancer Biol Ther 2004, 3(2):207–218.
18. Chu K, Teele N, Dewey MW, Albright N, Dewey WC: Computerized video
time lapse study of cell cycle delay and arrest, mitotic catastrophe,
apoptosis and clonogenic survival in irradiated 14-3-3sigma and
CDKN1A (p21) knockout cell lines. Radiat Res 2004, 162(3):270–286.
19. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA: Polyploid giant cells
provide a survival mechanism for p53 mutant cells after DNA damage.
Cell Biol Int 2000, 24(9):621–633.
20. Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, Bouyer F, Favier L,
Ghiringhelli F, Kroemer G, Solary E, et al: Tumor cells can escape
DNA-damaging cisplatin through DNA endoreduplication and reversible
polyploidy. Cell Biol Int 2008, 32(9):1031–1043.
21. Vitale I, Senovilla L, Jemaa M, Michaud M, Galluzzi L, Kepp O, Nanty L, Criollo A,
Rello-Varona S, Manic G, et al: Multipolar mitosis of tetraploid cells: inhibition
by p53 and dependency on Mos. EMBO J 2010, 29(7):1272–1284.
22. Erenpreisa J, Ivanov A, Wheatley SP, Kosmacek EA, Ianzini F, Anisimov AP,
Mackey M, Davis PJ, Plakhins G, Illidge TM: Endopolyploidy in irradiated
p53-deficient tumour cell lines: persistence of cell division activity in
giant cells expressing Aurora-B kinase. Cell Biol Int 2008, 32(9):1044–1056.
23. Ianzini F, Kosmacek EA, Nelson ES, Napoli E, Erenpreisa J, Kalejs M, Mackey
MA: Activation of meiosis-specific genes is associated with
Erenpreisa and Cragg Cancer Cell International 2013, 13:92 Page 10 of 12
http://www.cancerci.com/content/13/1/92depolyploidization of human tumor cells following radiation-induced
mitotic catastrophe. Cancer Res 2009, 69(6):2296–2304.
24. Nagl W: Endopolyploidy and polyteny in differentiation and evolution.
Amsterdam-New York: North-Holland: Publ. Comp.; 1978.
25. Davoli T, de Lange T: The causes and consequences of polyploidy in
normal development and cancer. Annu Rev Cell Dev Biol 2011, 27:585–610.
26. Zybina TG, Zybina EV: Cell cycle modification in trophoblast cell
populations in the course of placenta formation. A review. In DNA
replication and related cellular processes. Edited by Kusic-Tisma J. Rijeka:
Croatia: InTech; 2011:227–258.
27. Beermann W: Control of differentiation at the chromosomal level.
J Exp Zool 1964, 157:49–62.
28. Zybina E: Cytophotometric estimation of the amount of DNA in the nuclei of
the giant cells of the trophoblast. DoklAkadNauk SSSR 1963, 153:1428–1431.
29. Rivello HG, Meckert PC, Vigliano C, Favaloro R, Laguens RP: Cardiac
myocyte nuclear size and ploidy status decrease after mechanical
support. Cardiovasc Pathol 2001, 10(2):53–57.
30. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB,
Finegold MJ, Grompe M: The ploidy conveyor of mature hepatocytes as a
source of genetic variation. Nature 2010, 467(7316):707–710.
31. Erenpreisa JA, Cragg MS, Fringes B, Sharakhov I, Illidge TM: Release of
mitotic descendants by giant cells from irradiated Burkitt’s lymphoma
cell line. Cell Biol Int 2000, 24(9):635–648.
32. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM:
Endopolyploid cells produced after severe genotoxic damage have the
potential to repair DNA double strand breaks. J Cell Sci 2003, 116(Pt
20):4095–4106.
33. Erenpreisa J, Cragg MS, Anisimov AP, Illidge TM: Tumor cell embryonality
and the ploidy number 32n: is it a developmental checkpoint? Cell Cycle
2011, 10(11):1873–1874.
34. Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaa M, Castedo M, Kroemer G:
Illicit survival of cancer cells during polyploidization and
depolyploidization. Cell Death Differ 2011, 18(9):1403–1413.
35. Vakifahmetoglu H, Olsson M, Zhivotovsky B: Death through a tragedy:
mitotic catastrophe. Cell Death Differ 2008, 15(7):1153–1162.
36. Lu X, Kang Y: Cell fusion as a hidden force in tumor progression.
Cancer Res 2009, 69(22):8536–8539.
37. Gisselsson D, Hakanson U, Stoller P, Marti D, Jin Y, Rosengren AH, Stewenius
Y, Kahl F, Panagopoulos I: When the genome plays dice: circumvention of
the spindle assembly checkpoint and near-random chromosome
segregation in multipolar cancer cell mitoses. PLoS One 2008, 3(4):e1871.
38. Zasadil LM, Britigan EM, Weaver BA: 2n or not 2n: Aneuploidy, polyploidy
and chromosomal instability in primary and tumor cells. Semin Cell Dev
Biol 2013, 24(4):370–379.
39. Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey MA, Emzinsh D, Cragg
MS, Ivanov A, Illidge TM: Segregation of genomes in polyploid tumour
cells following mitotic catastrophe. Cell Biol Int 2005, 29(12):1005–1011.
40. Walen KH: Meiotic-like division to a aneuploidy: chromosomal instability
(CIN), cell-senescence and cancer. Cell Oncol 2008, 30(5):451–452.
41. Walen KH: Genetic stability of senescence reverted cells: genome
reduction division of polyploidy cells, aneuploidy and neoplasia.
Cell Cycle 2008, 7(11):1623–1629.
42. Walen KH: Mitosis is not the only distributor of mutated cells: non-mitotic
endopolyploid cells produce reproductive genome-reduced cells. Cell Biol
Int 2010, 34(8):867–872.
43. Erenpreisa J, Cragg MS, Salmina K, Hausmann M, Scherthan H: The role
of meiotic cohesin REC8 in chromosome segregation in gamma
irradiation-induced endopolyploid tumour cells. Exp Cell Res 2009,
315(15):2593–2603.
44. Davoli T, Denchi EL, de Lange T: Persistent telomere damage induces
bypass of mitosis and tetraploidy. Cell 2010, 141(1):81–93.
45. Erenpreisa J, Salmina K, Huna A, Kosmacek EA, Cragg M, Ianzini F,
Anisimov A: Polyploid tumour cells elicit para-diploid progeny
through de-polyploidising divisions and regulated autophagic
degradation. Cell Biol Int 2011, 35(7):687–695.
46. Erenpreisa J, Huna A, Salmina K, Jackson TR, Cragg MS: Macroautophagy-aided
elimination of chromatin: sorting of waste, sorting of fate? Autophagy 2012,
8(12):1877–1881.
47. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J: Generation of
cancer stem-like cells through the formation of polyploid giant cancer
cells. Oncogene 2013:1–13.48. Marxer M, Foucar CE, Man WY, Chen Y, Ma HT, Poon RY: Tetraploidization
increases sensitivity to Aurora B kinase inhibition. Cell Cycle 2012,
11(13):2567–2577.
49. Tam WL, Ang YS, Lim B: The molecular basis of ageing in stem cells.
Mech Ageing Dev 2007, 128(1):137–148.
50. Sabisz M, Skladanowski A: Cancer stem cells and escape from drug-induced
premature senescence in human lung tumor cells: implications for drug
resistance and in vitro drug screening models. Cell Cycle 2009, 8(19):3208–3217.
51. Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, Magalska A,
Szczepanowska J, Fronk J, Sikora E: Induction of senescence with
doxorubicin leads to increased genomic instability of HCT116 cells. Mech
Ageing Dev 2009, 130(1–2):24–32.
52. Mosieniak G, Sikora E: Polyploidy: the link between senescence and
cancer. Curr Pharm Des 2010, 16(6):734–740.
53. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY: Escape from therapy-
induced accelerated cellular senescence in p53-null lung cancer cells
and in human lung cancers. Cancer Res 2005, 65(7):2795–2803.
54. Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, Wu DY: Survivin
and escaping in therapy-induced cellular senescence. Int J Cancer 2011,
128(7):1546–1558.
55. Wang Q, Wu PC, Dong DZ, Ivanova I, Chu E, Zeliadt S, Vesselle H, Wu DY:
Polyploidy road to therapy-induced cellular senescence and escape. Int J
Cancer 2013, 132(7):1505–1515.
56. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT:
Aurora B kinase exists in a complex with survivin and INCENP and its
kinase activity is stimulated by survivin binding and phosphorylation.
Mol Biol Cell 2002, 13(9):3064–3077.
57. Bernstein H, Hopf FA, Michod RE: The molecular basis of the evolution of
sex. Adv Genet 1987, 24:323–370.
58. Kondrashov AS: The asexual ploidy cycle and the origin of sex.
Nature 1994, 370(6486):213–216.
59. Nebreda AR, Ferby I: Regulation of the meiotic cell cycle in oocytes.
Curr Opin Cell Biol 2000, 12(6):666–675.
60. Dernburg AF, McDonald K, Moulder G, Barstead R, Dresser M, Villeneuve AM:
Meiotic recombination in C. elegans initiates by a conserved mechanism
and is dispensable for homologous chromosome synapsis. Cell 1998, 94
(3):387–398.
61. Erenpreisa J, Kalejs M, Cragg MS: Mitotic catastrophe and endomitosis in
tumour cells: an evolutionary key to a molecular solution. Cell Biol Int
2005, 29(12):1012–1018.
62. Erenpreisa J, Cragg MS: Cancer: a matter of life cycle? Cell Biol Int 2007, 31
(12):1507–1510.
63. Erenpreisa J, Cragg MS: MOS, aneuploidy and the ploidy cycle of cancer
cells. Oncogene 2010, 29(40):5447–5451.
64. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, Erenpreisa J:
Upregulation of meiosis-specific genes in lymphoma cell lines following
genotoxic insult and induction of mitotic catastrophe. BMC Cancer 2006, 6:6.
65. Gorgoulis VG, Zacharatos P, Mariatos G, Liloglou T, Kokotas S, Kastrinakis N,
Kotsinas A, Athanasiou A, Foukas P, Zoumpourlis V, et al: Deregulated
expression of c-mos in non-small cell lung carcinomas: relationship with
p53 status, genomic instability, and tumor kinetics. Cancer Research 2001,
61(2):538–549.
66. Rosa AM, Dabas N, Byrnes DM, Eller MS, Grichnik JM: Germ cell proteins in
melanoma: prognosis, diagnosis, treatment, and theories on expression.
J Skin Cancer 2012, 2012:621968.
67. Nasmyth K: Disseminating the genome: joining, resolving, and separating
sister chromatids during mitosis and meiosis. Annu Rev Genet 2001,
35:673–745.
68. Dupre A, Haccard O, Jessus C: Mos in the oocyte: how to use MAPK
independently of growth factors and transcription to control meiotic
divisions. J Signal Transduct 2011, 2011:350412.
69. Dupre A, Suziedelis K, Valuckaite R, de Gunzburg J, Ozon R, Jessus C,
Haccard O: Xenopus H-RasV12 promotes entry into meiotic M phase and
cdc2 activation independently of Mos and p42(MAPK). Oncogene 2002,
21(42):6425–6433.
70. Fukasawa K, Murakami MS, Blair DG, Kuriyama R, Hunt T, Fischinger P, Vande
Woude GF: Similarities between somatic cells overexpressing the mos
oncogene and oocytes during meiotic interphase. Cell Growth Differ 1994,
5(10):1093–1103.
71. Erenpreiss J: Current concepts of malignant growth. Riga: Part A. From a
normal cell to cancer Zvaigzne Publishers; 1993:191.
Erenpreisa and Cragg Cancer Cell International 2013, 13:92 Page 11 of 12
http://www.cancerci.com/content/13/1/9272. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G: The DNA damage signaling
pathway is a critical mediator of oncogene-induced senescence. Genes &
Development 2007, 21(1):43–48.
73. Hasan AKMMT, Kihira M, Yoshida J, Sato K-I: In Phospho-Signaling at Oocyte
Maturation and Fertilization: Set Up for Embryogenesis and Beyond Part I.




74. Johnson AD, Cork RJ, Williams MA, Robinson KR, Smith LD: H-ras(val12)
induces cytoplasmic but not nuclear events of the cell cycle in small
Xenopus oocytes. Cell Regul 1990, 1(7):543–554.
75. Back JH, Kim AL: The expanding relevance of nuclear mTOR in
carcinogenesis. Cell Cycle 2011, 10(22):3849–3852.
76. Laplante M, Sabatini DM: mTOR signaling in growth control and disease.
Cell 2012, 149(2):274–293.
77. Birchmeier C, Broek D, Wigler M: Ras proteins can induce meiosis in
Xenopus oocytes. Cell 1985, 43(3 Pt 2):615–621.
78. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev
Cancer 2005, 5(4):275–284.
79. Jordan CT, Guzman ML, Noble M: Cancer stem cells. N Engl J Med 2006,
355(12):1253–1261.
80. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA:
An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet 2008, 40(5):499–507.
81. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C,
Kusunoki M: Correlation of CD133, OCT4, and SOX2 in rectal cancer and
their association with distant recurrence after chemoradiotherapy. Ann
Surg Oncol 2009, 16(12):3488–3498.
82. Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, Jin T, Cai XY, Liang Y, Hu WH,
et al: Prognostic significance of Oct4 and Sox2 expression in
hypopharyngeal squamous cell carcinoma. J Transl Med 2010, 8:94.
83. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reisfeld
RA, Luo Y: Downregulation of transcription factor SOX2 in cancer stem
cells suppresses growth and metastasis of lung cancer. Br J Cancer 2011,
104(9):1410–1417.
84. Baumann M, Krause M, Hill R: Exploring the role of cancer stem cells in
radioresistance. Nat Rev Cancer 2008, 8(7):545–554.
85. Blagosklonny MV: Target for cancer therapy: proliferating cells or stem
cells. Leukemia 2006, 20(3):385–391.
86. Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov
A, Jascenko E, Scherthan H, Cragg M, et al: Up-regulation of the embryonic
self-renewal network through reversible polyploidy in irradiated p53-
mutant tumour cells. Exp Cell Res 2010, 316(13):2099–2112.
87. Lee GY, Shim JS, Cho B, Jung JY, Lee DS, Oh IH: Stochastic acquisition of a
stem cell-like state and drug tolerance in leukemia cells stressed by
radiation. Int J Hematol 2011, 93(1):27–35.
88. Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ: Ionizing radiation induces
stemness in cancer cells. PLoS One 2012, 7(8):e43628.
89. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F: Radiation-induced
reprogramming of breast cancer cells. Stem Cells 2012, 30(5):833–844.
90. Chuang YS, Huang WH, Park SW, Persaud SD, Hung CH, Ho PC, Wei LN:
Promyelocytic leukemia protein in retinoic acid-induced chromatin
remodeling of Oct4 gene promoter. Stem Cells 2011, 29(4):660–669.
91. Bartova E, Sustackova G, Stixova L, Kozubek S, Legartova S, Foltankova V:
Recruitment of Oct4 protein to UV-damaged chromatin in embryonic
stem cells. PLoS One 2011, 6(12):e27281.
92. Guo Y, Mantel C, Hromas RA, Broxmeyer HE: Oct-4 is critical for survival/
antiapoptosis of murine embryonic stem cells subjected to stress: effects
associated with Stat3/survivin. Stem Cells 2008, 26(1):30–34.
93. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126
(4):663–676.
94. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC,
Azuara V, Walsh M, et al: Senescence impairs successful reprogramming
to pluripotent stem cells. Genes Dev 2009, 23(18):2134–2139.
95. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA,
Serrano M: The Ink4/Arf locus is a barrier for iPS cell reprogramming.
Nature 2009, 460(7259):1136–1139.
96. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufi S, Vazquez-Martin A: mTOR-
regulated senescence and autophagy during reprogramming of somaticcells to pluripotency: a roadmap from energy metabolism to stem cell
renewal and aging. Cell Cycle 2011, 10(21):3658–3677.
97. Huna A, Salmina K, Jascenko E, Duburs G, Inashkina I, Erenpreisa J: Self-
Renewal Signalling in Presenescent Tetraploid IMR90 Cells. J Aging Res
2011, 2011:103253.
98. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM: DNA double-
stranded breaks induce histone H2AX phosphorylation on serine 139.
J Biol Chem 1998, 273(10):5858–5868.
99. Boheler KR: Stem cell pluripotency: a cellular trait that depends on
transcription factors, chromatin state and a checkpoint deficient cell
cycle. J Cell Physiol 2009, 221(1):10–17.
100. Mantel C, Guo Y, Lee MR, Kim MK, Han MK, Shibayama H, Fukuda S, Yoder
MC, Pelus LM, Kim KS, et al: Checkpoint-apoptosis uncoupling in human
and mouse embryonic stem cells: a source of karyotpic instability. Blood
2007, 109(10):4518–4527.
101. Mantel C, Guo Y, Lee MR, Han MK, Rhorabough S, Kim KS, Broxmeyer HE:
Cells enter a unique intermediate 4N stage, not 4N-G1, after aborted
mitosis. Cell Cycle 2008, 7(4):484–492.
102. Conant GC, Wolfe KH: Increased glycolytic flux as an outcome of whole-
genome duplication in yeast. Mol Syst Biol 2007, 3:129.
103. Anatskaya OV, Vinogradov AE: Genome multiplication as adaptation to
tissue survival: evidence from gene expression in mammalian heart and
liver. Genomics 2007, 89(1):70–80.
104. Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark
even Warburg did not anticipate. Cancer Cell 2012, 21(3):297–308.
105. Hu J, Locasale JW, Bielas JH, O’Sullivan J, Sheahan K, Cantley LC, Heiden MGV,
Vitkup D: Heterogeneity of tumor-induced gene expression changes in the
human metabolic network. Nat Biotech 2013, 31(6):522–529.
106. Jiang J, Tang YL, Liang XH: EMT: a new vision of hypoxia promoting
cancer progression. Cancer Biol Ther 2011, 11(8):714–723.
107. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K: c-Myc and cancer
metabolism. Clin Cancer Res 2012, 18(20):5546–5553.
108. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen
R, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase
isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Proc Natl Acad Sci U S A 2011, 108(10):4129–4134.
109. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY: Module map of
stem cell genes guides creation of epithelial cancer stem cells. Cell Stem
Cell 2008, 2(4):333–344.
110. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway
DA, Gu W, Gautier J, Dalla-Favera R: Non-transcriptional control of DNA
replication by c-Myc. Nature 2007, 448(7152):445–451.
111. Li Q, Dang CV: c-Myc overexpression uncouples DNA replication from
mitosis. Mol Cell Biol 1999, 19(8):5339–5351.
112. Conner EA, Lemmer ER, Sanchez A, Factor VM, Thorgeirsson SS: E2F1 blocks
and c-Myc accelerates hepatic ploidy in transgenic mouse models.
Biochem Biophys Res Commun 2003, 302(1):114–120.
113. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer
M, Graf N, Scheerer M, Hall MA, et al: Aurora kinases A and B are up-
regulated by Myc and are essential for maintenance of the malignant
state. Blood 2010, 116(9):1498–1505.
114. Gusse M, Ghysdael J, Evan G, Soussi T, Mechali M: Translocation of a store
of maternal cytoplasmic c-myc protein into nuclei during early
development. Mol Cell Biol 1989, 9(12):5395–5403.
115. Gordon DJ, Resio B, Pellman D: Causes and consequences of aneuploidy
in cancer. Nat Rev Genet 2012, 13(3):189–203.
116. Jackson TR, Salmina K, Huna A, Inashkina I, Jankevics E, Riekstina U, Kalnina
Z, Ivanov A, Townsend PA, Cragg MS, et al: DNA damage causes TP53-
dependent coupling of self-renewal and senescence pathways in
embryonal carcinoma cells. Cell Cycle 2013, 12(3):430–441.
117. Sherman MY, Meng L, Stampfer M, Gabai VL, Yaglom JA: Oncogenes
induce senescence with incomplete growth arrest and suppress the
DNA damage response in immortalized cells. Aging Cell 2011,
10(6):949–961.
118. Zybina TG, Stein GI, Zybina EV: Endopolyploid and proliferating trophoblast
cells express different patterns of intracellular cytokeratin and glycogen
localization in the rat placenta. Cell Biol Int 2011, 35(7):649–655.
119. Lee J, Go Y, Kang I, Han YM, Kim J: Oct-4 controls cell-cycle progression of
embryonic stem cells. Biochem J 2010, 426(2):171–181.
120. Raderschall E, Bazarov A, Cao J, Lurz R, Smith A, Mann W, Ropers HH, Sedivy
JM, Golub EI, Fritz E, et al: Formation of higher-order nuclear Rad51
Erenpreisa and Cragg Cancer Cell International 2013, 13:92 Page 12 of 12
http://www.cancerci.com/content/13/1/92structures is functionally linked to p21 expression and protection from
DNA damage-induced apoptosis. J Cell Sci 2002, 115(Pt 1):153–164.
121. Zheng L, Dai H, Zhou M, Li X, Liu C, Guo Z, Wu X, Wu J, Wang C, Zhong J,
et al: Polyploid cells rewire DNA damage response networks to
overcome replication stress-induced barriers for tumour progression. Nat
Commun 2012, 3:815.
122. Huang S: Reprogramming cell fates: reconciling rarity with robustness.
Bioessays 2009, 31(5):546–560.
123. Huang S: Non-genetic heterogeneity of cells in development: more than
just noise. Dev 2009, 136(23):3853–3862.
124. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR: Neosis - A
parasexual somatic reduction division in cancer. Int J Hum Genet 2007,
7(1):29–48.
125. Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ: Formation of solid tumors by
a single multinucleated cancer cell. Cancer 2011, 117(17):4092–4099.
126. Young AR, Narita M: Connecting autophagy to senescence in
pathophysiology. Curr Opin Cell Biol 2010, 22(2):234–240.
127. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell
2011, 144(5):646–674.
128. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting.
Annu Rev Immunol 2004, 22:329–360.
129. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis
antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5(8):615–625.
130. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L,
Maio M: The biology of cancer testis antigens: putative function,
regulation and therapeutic potential. Mol Oncol 2011, 5(2):164–182.
131. Lindsey SF, Byrnes DM, Eller MS, Rosa AM, Dabas N, Escandon J, Grichnik JM:
Potential role of meiosis proteins in melanoma chromosomal instability.
J Skin Cancer 2013, 2013:1–9. http://dx.doi.org/10.1155/2013/1901099.
132. Zayakin P, Ancans G, Silina K, Meistere I, Kalnina Z, Andrejeva D, Endzelins E,
Ivanova L, Pismennaja A, Ruskule A, et al: Tumor-associated autoantibody
signature for the early detection of gastric cancer. Int J Cancer 2013, 132
(1):137–147.
133. Boileve A, Senovilla L, Vitale I, Lissa D, Martins I, Metivier D, van den Brink S,
Clevers H, Galluzzi L, Castedo M, et al: Immunosurveillance against
tetraploidization-induced colon tumorigenesis. Cell Cycle 2013, 12(3):473–479.
134. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L,
Adjemian S, Kepp O, Niso-Santano M, et al: An immunosurveillance
mechanism controls cancer cell ploidy. Science 2012, 337(6102):1678–1684.
135. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L,
Menendez JA: Autophagy positively regulates the CD44(+) CD24(−/low)
breast cancer stem-like phenotype. Cell Cycle 2011, 10(22):3871–3885.
136. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau
P, Badoual C, Vielh P, Larsen AK, et al: Epithelial-to-mesenchymal transition
and autophagy induction in breast carcinoma promote escape from T-
cell-mediated lysis. Cancer Res 2013, 73(8):2418–2427.
137. Wells D, Hillier SG: Polar bodies: their biological mystery and clinical
meaning. Mol Hum Reprod 2011, 17(5):273–274.
138. Lu E, Wolfe J: Lysosomal enzymes in the macronucleus of Tetrahymena
during its apoptosis-like degradation. Cell Death Differ 2001, 8(3):289–297.
139. Raikov IB: The protozoan nucleus – morphology and evolution. Wien u.a:
Springer; 1982. 1983.
140. Marsh TC, Cole ES, Stuart KR, Campbell C, Romero DP: RAD51 is required
for propagation of the germinal nucleus in Tetrahymena thermophila.
Genetics 2000, 154(4):1587–1596.
141. Erenpreisa J, Cragg MS: Life-cycle features of tumour cells, Evolutionary biology
from concept to application. Germany: Springer-Verlag Berlin; 2008:61–71.
142. Mintz B, Illmensee K: Normal genetically mosaic mice produced from
malignant teratocarcinoma cells. Proc Natl Acad Sci U S A 1975, 72(9):3585–3589.
143. Yeom YI, Fuhrmann G, Ovitt CE, Brehm A, Ohbo K, Gross M, Hubner K,
Scholer HR: Germline regulatory element of Oct-4 specific for the
totipotent cycle of embryonal cells. Dev 1996, 122(3):881–894.
144. Zuccotti M, Merico V, Belli M, Mulas F, Sacchi L, Zupan B, Redi CA, Prigione
A, Adjaye J, Bellazzi R, et al: OCT4 and the acquisition of oocyte
developmental competence during folliculogenesis. Int J Dev Biol 2012,
56(10–12):853–858.
145. Wang X, Dai J: Concise review: isoforms of OCT4 contribute to the
confusing diversity in stem cell biology. Stem Cells 2010, 28(5):885–893.
146. Hubner K, Fuhrmann G, Christenson LK, Kehler J, Reinbold R, De La Fuente
R, Wood J, Strauss JF 3rd, Boiani M, Scholer HR: Derivation of oocytes from
mouse embryonic stem cells. Science 2003, 300(5623):1251–1256.147. Huang S, Ernberg I, Kauffman S: Cancer attractors: a systems view of
tumors from a gene network dynamics and developmental perspective.
Semin Cell Dev Biol 2009, 20(7):869–876.
148. Huang S: On the intrinsic inevitability of cancer: from foetal to fatal
attraction. Semin Cancer Biol 2011, 21(3):183–199.
149. Lipkin G: Plasticity of the cancer cell: implications for epigenetic control
of melanoma and other malignancies. J Invest Dermatol 2008,
128(9):2152–2155.
150. Baylin SB, Jones PA: A decade of exploring the cancer epigenome -
biological and translational implications. Nat Rev Cancer 2011, 11(10):726–734.
151. Tsai HC, Baylin SB: Cancer epigenetics: linking basic biology to clinical
medicine. Cell Res 2011, 21(3):502–517.
152. Bissell M: Q&A: Mina Bissell on tumors as organs. Cancer Discov 2013, 3(1):7.
doi:10.1186/1475-2867-13-92
Cite this article as: Erenpreisa and Cragg: Three steps to the immortality
of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell
International 2013 13:92.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
